EU agency accepts Sandoz application for pegfilgrastim biosimilar

ZURICH (Reuters) - The European Medicines Agency (EMA) has accepted an application to review Sandoz's biosimilar to Amgen's EU-licensed Neulasta (pegfilgrastim), a recombinant human granulocyte colony-stimulating factor, Sandoz parent Novartis said on Thursday.

http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro